389 related articles for article (PubMed ID: 23613015)
1. Current insights into animal models of Graves' disease and orbitopathy.
Wiesweg B; Johnson KT; Eckstein AK; Berchner-Pfannschmidt U
Horm Metab Res; 2013 Aug; 45(8):549-55. PubMed ID: 23613015
[TBL] [Abstract][Full Text] [Related]
2. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.
Moshkelgosha S; So PW; Deasy N; Diaz-Cano S; Banga JP
Endocrinology; 2013 Sep; 154(9):3008-15. PubMed ID: 23900776
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
[TBL] [Abstract][Full Text] [Related]
5. Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease.
Kita M; Ahmad L; Marians RC; Vlase H; Unger P; Graves PN; Davies TF
Endocrinology; 1999 Mar; 140(3):1392-8. PubMed ID: 10067867
[TBL] [Abstract][Full Text] [Related]
6. Critical Differences between Induced and Spontaneous Mouse Models of Graves' Disease with Implications for Antigen-Specific Immunotherapy in Humans.
Rapoport B; Banuelos B; Aliesky HA; Hartwig Trier N; McLachlan SM
J Immunol; 2016 Dec; 197(12):4560-4568. PubMed ID: 27913646
[TBL] [Abstract][Full Text] [Related]
7. Review of Mouse Models of Graves' Disease and Orbitopathy-Novel Treatment by Induction of Tolerance.
Ungerer M; Faßbender J; Li Z; Münch G; Holthoff HP
Clin Rev Allergy Immunol; 2017 Apr; 52(2):182-193. PubMed ID: 27368808
[TBL] [Abstract][Full Text] [Related]
8. An improved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice.
Kaneda T; Honda A; Hakozaki A; Fuse T; Muto A; Yoshida T
Endocrinology; 2007 May; 148(5):2335-44. PubMed ID: 17255207
[TBL] [Abstract][Full Text] [Related]
9. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor.
Nagayama Y; Kita-Furuyama M; Ando T; Nakao K; Mizuguchi H; Hayakawa T; Eguchi K; Niwa M
J Immunol; 2002 Mar; 168(6):2789-94. PubMed ID: 11884447
[TBL] [Abstract][Full Text] [Related]
10. Cre-loxP System-Based Mouse Model for Investigating Graves' Disease and Associated Orbitopathy.
Bao Y; Kim D; Cho YH; Ku CR; Yoon JS; Lee EJ
Thyroid; 2023 Nov; 33(11):1358-1367. PubMed ID: 37624749
[No Abstract] [Full Text] [Related]
11. Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy.
Boschi A; Daumerie Ch; Spiritus M; Beguin C; Senou M; Yuksel D; Duplicy M; Costagliola S; Ludgate M; Many MC
Br J Ophthalmol; 2005 Jun; 89(6):724-9. PubMed ID: 15923509
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease.
Masetti G; Moshkelgosha S; Köhling HL; Covelli D; Banga JP; Berchner-Pfannschmidt U; Horstmann M; Diaz-Cano S; Goertz GE; Plummer S; Eckstein A; Ludgate M; Biscarini F; Marchesi JR;
Microbiome; 2018 May; 6(1):97. PubMed ID: 29801507
[TBL] [Abstract][Full Text] [Related]
13. Animal models of Graves' disease and Graves' orbitopathy.
Nagayama Y; Nakahara M; Abiru N
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):381-6. PubMed ID: 26181432
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of antithyrotropin receptor (TSHR) autoimmunity from TSHR knockout mice to athymic nude mice.
Nakahara M; Johnson K; Eckstein A; Taguchi R; Yamada M; Abiru N; Nagayama Y
Endocrinology; 2012 Apr; 153(4):2034-42. PubMed ID: 22334716
[TBL] [Abstract][Full Text] [Related]
15. Immunization of mice with a newly identified thyroid-stimulating hormone receptor splice variant induces Graves'-like disease.
Endo T; Kobayashi T
J Autoimmun; 2013 Jun; 43():18-25. PubMed ID: 23538203
[TBL] [Abstract][Full Text] [Related]
16. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
[TBL] [Abstract][Full Text] [Related]
17. Generation of a transgenic animal model of hyperthyroid Graves' disease.
Kim-Saijo M; Akamizu T; Ikuta K; Iida Y; Ohmori K; Matsubara K; Matsuda Y; Suzuki M; Matsuda F; Nakao K
Eur J Immunol; 2003 Sep; 33(9):2531-8. PubMed ID: 12938229
[TBL] [Abstract][Full Text] [Related]
18. The role of genetics in Graves' disease and thyroid orbitopathy.
Kim N; Hatton MP
Semin Ophthalmol; 2008; 23(1):67-72. PubMed ID: 18214794
[TBL] [Abstract][Full Text] [Related]
19. Animal model of thyroid-associated orbitopathy.
Ludgate M
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 5():S158-9. PubMed ID: 10614911
[TBL] [Abstract][Full Text] [Related]
20. Preclinical models of Graves' disease and associated secondary complications.
Moshkelgosha S; So PW; Diaz-Cano S; Banga JP
Curr Pharm Des; 2015; 21(18):2414-21. PubMed ID: 25777757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
